PROCEPT BioRobotics gets FDA okay for prostate cancer study

PROCEPT BioRobotics (NASDAQ: PRCT ) said it has received FDA approval to conduct a study investigating the safety and efficacy of Aquablation therapy in the treatment of prostate cancer. PROCEPT said the study’s findings will be used to support future research and US regulatory applications. The single-arm feasibility study […]

Click here to view original web page at www.msn.com